Skip to main content

Table 5 Results of multivariate analyses

From: Single nucleotide polymorphisms in apoptosis pathway are associated with response to imatinib therapy in chronic myeloid leukemia

Risk factor

Referent parameter

Adverse parameter

Univariate p value

Multivariate p value

HR (95 % CI)

MCR

 FAS (rs2234978)

CT/TT

CC

0.026

0.062

0.52 (0.26–1.03)

 Age, continuous

–

–

0.748

0.920

1.00 (0.99–1.01)

 Prior treatment

No

Yes

0.009

0.060

0.56 (0.30–1.03)

 ACA

Absent

Present

0.128

0.560

0.85 (0.50–1.45)

 Disease stage

AP/BC

CP

0.450

0.190

1.98 (0.72–5.46)

CCR

 FAS (rs2234978)

CT/TT

CC

0.036

0.100

0.56 (0.28–1.12)

 Age, continuous

–

–

0.796

0.910

0.99 (0.98–1.01)

 Prior treatment

No

Yes

0.016

0.074

0.57 (0.31–1.05)

 ACA

Absent

Present

0.496

0.330

0.77 (0.45–1.30)

 Disease stage

AP/BC

CP

0.399

0.060

2.48 (0.96–6.38)

MMR

 FAS (rs2234978)

CT/TT

CC

0.050

0.022*

0.53 (0.30–0.91)

 FASLG (rs763110)

CT/TT

CC

0.017

0.079

1.42 (0.96–2.11)

 Age, continuous

–

–

0.670

0.880

0.99 (0.98–1.01)

 Prior treatment

No

Yes

0.002

0.007**

0.44 (0.24–0.80)

 ACA

Absent

Present

0.097

0.490

0.81 (0.44–1.48)

 Disease stage

AP/BC

CP

0.235

0.062

2.48 (0.96–6.44)

MR4.5

 FAS (rs2234767)

GA/GG

AA

0.013

0.019*

0.43 (0.22–0.87)

 FAS (rs2234978)

CT/TT

CC

0.011

0.003**

0.45 (0.26–0.77)

 Age, continuous

–

–

0.911

0.470

0.99 (0.98–1.01)

 Prior treatment

No

Yes

0.011

0.051

0.50 (0.25–1.00)

 ACA

Absent

Present

0.110

0.930

0.97 (0.46–2.02)

 Disease stage

AP/BC

CP

0.316

0.110

3.17 (0.76–13.17)

LOR

 APAF1 (rs1439123)

TT

CT/CC

0.011

0.174

0.36 (0.08–1.57)

 FAS (rs2234767)

GA/GG

AA

0.034

0.177

2.21 (0.70–7.02)

 Age, continuous

–

–

 

0.875

0.99 (0.96–1.03)

 Prior treatment

No

Yes

0.062

0.538

1.47 (0.43–5.06)

 ACA

Absent

Present

0.973

0.918

1.08 (0.24–4.89)

 Disease stage

AP/BC

CP

0.432

0.607

1.77 (0.20–15.43)

TF

 CASP10 (rs13006529)

TA/AA

TT

0.025

0.049*

0.57 (0.32–0.99)

 Age, continuous

–

–

0.978

0.869

0.99 (0.97–1.02)

 Prior treatment

No

Yes

0.039

0.040*

1.94 (1.03–3.67)

 ACA

Absent

Present

0.257

0.483

1.31 (0.61–2.81)

 Disease stage

AP/BC

CP

0.001

0.093

0.47 (0.20–1.13)

PFS

 FASLG (rs763110)

CT/TT

CC

0.001

0.003**

0.04 (0.01–0.36)

 Age, continuous

–

–

0.765

0.260

0.98 (0.94–1.02)

 Prior treatment

No

Yes

0.235

0.053

3.28 (0.98–10.90)

 ACA

Absent

Present

0.093

0.018*

4.36 (1.29–14.71)

 Disease stage

AP/BC

CP

0.873

0.251

3.58 (0.41–31.68)

OS

 CASP10 (rs13006529)

TA/AA

TT

0.019

0.050*

0.25 (0.06–1.00)

 FASLG (rs763110)

CT/TT

CC

0.020

0.046*

0.12 (0.01–0.97)

 Age, continuous

–

–

0.787

0.300

0.97 (0.92–1.02)

 Prior treatment

No

Yes

0.225

0.170

2.75 (0.65–11.64)

 ACA

Absent

Present

0.441

0.175

3.07 (0.61–15.51)

 Disease stage

AP/BC

CP

0.917

0.377

2.94 (0.27–32.15)

  1. ACA additional cytogenetic abnormality, HR hazard ratio, SNP single nucleotide polymorphism, MCR major cytogenetic response, CCR complete cytogenetic response, MMR major molecular response, MR4.5 molecular response with 4.5 log reduction, LOR loss of response, TF treatment failure, PFS progression free survival, OS overall survival, APAF1 apoptotic peptidase activating factor 1, CASP10 caspase 10, FAS Fas cell surface death receptor, FASLG Fas ligand (TNF receptor superfamily member 6)
  2. * P < 0.05/** P < 0.01
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us